Effect of Non Invasive Brain Stimulation on Experimentally Induced Dyspnea (Breathlessness) (tDCS-Dyspnea)

Effect of Transcranial Direct Current Stimulation (tDCS) on Acutely Induced Dyspnea in Healthy Volunteers : a Pilot Study

Dyspnea is a frequent, mostly unpleasant and long-lasting, but also often undertreated symptom. Transcranial direct current stimulation (tDCS), a new non invasive method to modify brain activation has shown good efficacy in the treatment of pain especially in the clinical context. Given the fact that dyspnea has many common characteristics with pain, especially concerning the brain areas involved in its central processing, we hypothesize that tDCS may also modify the perception of dyspnea. In order to test this, we first shall determine whether tDCS has a significant effect on acutely induced dyspnea in healthy volunteers. In case of promising results of this pilot study, the next step will be the evaluation of the benefit of tDCS in patients with severe dyspnea.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Dyspnea will be induced by breathing through a combination of an external resistive load and a long tube (inducing CO2 rebreathing) (resulting in a sensation of both increased respiratory effort and air hunger). tDCS will be applied during 15 minutes either over the motor/premotor or over the insular cortex (i.e. 2 brain regions that have previously been shown to be involved in dyspnea perception and/or modulation) in 2 parallel groups of healthy subjects. For each study group, the effect of tDCS on dyspnea perception and on respiratory parameters will be compared between 2 active (anodal and cathodal) and a sham tDCS stimulation (placebo).

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Garches, France, 92380
        • Hôpital Raymond Poincaré

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Registered at the National List of persons taking part in clinical research
  • Signed consent form
  • Subjects of both genders aged of at least 18 years
  • Perfect understanding of the instructions and of sensory scaling
  • Prior medical examination

Exclusion Criteria:

  • Any current or past disease, in particular respiratory, neurological and psychiatric disorders
  • Regular use of drugs, especially those having an impact on respiratory, neurological systems (most specifically those with an effect on the central nervous system)
  • Unwilling to participate
  • Vulnerable people as defined in the provisions relating to biomedical researches and described in the Code of Public Health.
  • Unable to cooperate
  • Pregnancy or lactation
  • No affiliation to a social security system.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: motor/premotor cortex stimulation
Active and sham tDCS applied over the motor/premotor cortex

Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit

  • Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min
  • Cathodal tDCS: Intensity of 1.25 mA during 15 min
  • Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)
Other Names:
  • Eldith DC stimulator (Magstim Company Ltd. UK)
Experimental: insular cortex stimulation
Active and sham tDCS applied over the insular cortex

Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit

  • Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min
  • Cathodal tDCS: Intensity of 1.25 mA during 15 min
  • Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)
Other Names:
  • Eldith DC stimulator (Magstim Company Ltd. UK)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of active versus sham tDCS on perceived intensity (sensory component) of induced dyspnea
Time Frame: About 90 min (duration of the study visit)
Change from baseline (before tDCS application) in intensity of experimentally induced dyspnea (in Borg scale scores) at 4 different time points, 1 during and 3 after each of the 3 tDCS applications (anodal, cathodal and sham)
About 90 min (duration of the study visit)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of active versus sham tDCS on perceived unpleasantness (affective component) of induced dyspnea
Time Frame: About 90 min (duration of the study visit)
Change from baseline (before tDCS application) in unpleasantness of experimentally induced dyspnea (in Borg scale scores) at 4 different time points, 1 during and 3 after each of the 3 tDCS applications (anodal, cathodal and sham)
About 90 min (duration of the study visit)
Effect of active versus sham tDCS on respiratory variables during induced dyspnea
Time Frame: About 90 min (duration of the study visit)
Change from baseline (before tDCS application) in mouth pressure swings (cm H2O), tidal volume (L), respiratory frequency (cycles/min), minute ventilation (L/min) and end tidal carbon dioxide (PetCO2)(mm Hg) at 4 different time points, 1 during and 3 after each of the 3 tDCS applications (anodal, cathodal and sham)
About 90 min (duration of the study visit)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: CLAUDINE PEIFFER, MD PHD, Hôpital Raymond Poincaré

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2013

Primary Completion (Actual)

March 1, 2014

Study Completion (Actual)

April 1, 2014

Study Registration Dates

First Submitted

July 1, 2013

First Submitted That Met QC Criteria

July 1, 2013

First Posted (Estimate)

July 4, 2013

Study Record Updates

Last Update Posted (Estimate)

May 6, 2014

Last Update Submitted That Met QC Criteria

May 5, 2014

Last Verified

May 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyspnea

Clinical Trials on tDCS

3
Subscribe